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Introduction: EpiFibro (Brazilian Epidemiological Study of Fibromyalgia) was created to study
Fibromyalgia patients. Patients were included since 2011 according to the 1990 American
College of Rheumatology Classiﬁcation Criteria for Fibromyalgia (ACR1990).
Objectives: To determine how many patients still fulﬁll the ACR1990 and the ACR2010 criteria
in  2014; to determine the correlation between the impact of FM and to describe data on the
follow-up evaluation.
Methods: This is a cross sectional study in a multicenter cohort of patients. The data was
collected between 2013 and 2015. Physician included patients that fulﬁlled the ACR1990
criteria on the date of entry. The follow-up data were considered only for patients with at
least  two evaluations. A minimally signiﬁcant change was considered to be a 30% variationof  parameters scores.
Results: 810 patients’ data were analyzed. Patients presented a mean age of 51.8 ± 11.5 yearsPlease cite this article in press as: Martinez JE, et al. EpiFibro (Brazilian Fibromyalgia Registry): data on the ACR classiﬁcation and diagnostic
preliminary criteria fulﬁllment and the follow-up evaluation. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.012
old.  There were 786 female. Most patients met both criteria. There was  a greater fulﬁll-
ing  of the ACR2010. There was a moderate correlation between Polysymptomatic Distress
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Scale and Fibromyalgia Impact Questionnaire. Three hundred fourteen patients with more
than  one assessment were found, but 88 patients were excluded. Thus, 226 patients with
one follow-up monitoring parameter were considered (Fibromyalgia Impact Questionnaire:
222;  Polysymptomatic Distress Scale: 199; both: 195). The mean follow-up time was 9.1 ± 7.5
months (1–44). Most patients became stable.
Conclusion: InEpiFibro, most patients fulﬁll simultaneously the ACR1990 and ACR2010. A
larger number of patients fulﬁll the ACR2010 at the time of the evaluation. There was a
moderate correlation between the Polysymptomatic Distress Scale and the Fibromyalgia
Impact Questionnaire. Most patients remained stable over time.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
EpiFibro  (Registro  Brasileiro  de  Fibromialgia):  dados  sobre  a  classiﬁcac¸ão
do  ACR  e  preenchimento  dos  critérios  diagnósticos  preliminares  e
avaliac¸ão  de  seguimento
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Seguimento
r  e  s  u  m  o
Introduc¸ão: O EpiFibro (Estudo Epidemiológico Brasileiro de Fibromialgia) foi criado para
estudar pacientes com ﬁbromialgia. Foram incluídos pacientes desde 2011 de acordo com
os  critérios de classiﬁcac¸ão para a ﬁbromialgia do American College of Rheumatology de 1990
(ACR1990).
Objetivos: Determinar quantos pacientes ainda atendem aos critérios ACR1990 e ACR2010 em
2014;  determinar a correlac¸ão entre o impacto da FM medido pelo Questionário de Impacto
da  Fibromialgia (FIQ) e pela Polysymptomatic Distress Scale (PDS) e descrever dados sobre a
avaliac¸ão  de seguimento.
Métodos: Estudo transversal em uma coorte multicêntrica de pacientes. Os dados foram cole-
tados entre 2013 e 2015. O médico incluiu pacientes que atenderam aos critérios ACR1990
no  momento da entrada. Consideraram-se os dados de seguimento apenas dos pacientes
com  pelo menos duas avaliac¸ões. Uma variac¸ão de 30% nos escores dos parâmetros foi
considerada uma alterac¸ão minimamente signiﬁcativa.
Resultados: Analisaram-se os dados de 810 pacientes. Os pacientes apresentaram média
de  51,8 ± 11,5 anos. Havia 786 mulheres. A maior parte dos pacientes atendeu a ambos os
critérios. Houve um maior atendimento aos critérios ACR2010. Houve uma correlac¸ão mod-
erada entre a PDS e o FIQ. Encontraram-se 314 pacientes com mais de uma avaliac¸ão, mas
88  pacientes foram excluídos. Assim, foram considerados 226 pacientes com um parâmetro
de  monitoramento no seguimento. (FIQ: 222; PDS: 199; ambos: 195). O tempo médio de
seguimento foi de 9,1 ± 7,5 meses (1 a 44). A maior parte dos pacientes tornou-se estável.
Conclusão: No EpiFibro, a maior parte dos pacientes atendia simultaneamente ao ACR1990
e  ao ACR2010. Uma maior quantidade de pacientes atendia ao ACR2010 no momento da
avaliac¸ão.  Houve uma correlac¸ão moderada entre o Polysymptomatic Distress Scale e o
Questionário de Impacto da Fibromialgia. A maior parte dos pacientes manteve-se estável
ao  longo do tempo.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCSigniﬁcance  and  innovation
Brazilian Registry on Fibromyalgia. Fulﬁllment of ACR classiﬁ-
cation and diagnostic criteria. Follow-up data
IntroductionPlease cite this article in press as: Martinez JE, et al. EpiFibro (Brazilian F
preliminary criteria fulﬁllment and the follow-up evaluation. Rev Bras Reu
The Fibromyalgia Syndrome (FM) is a clinical condition char-
acterized by chronic widespread pain usually associated
to fatigue, sleep disturbances and cognitive symptoms. ItsBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
prevalence is high and in Brazil it is estimated at 2.5%.1 The
inﬂuence of social, psychological and cultural aspects makes
its clinical expression highly variable. There remains the need
for epidemiological studies on FM in our country.
The EpiFibro (Brazilian Epidemiological Study of Fibromyal-
gia) was created in order to analyze the epidemiology
of FM and its comorbidities across the country. It shall
offer better conditions to diagnosis, treat and evaluate the
impact of this disorder in Brazilian society through onlineibromyalgia Registry): data on the ACR classiﬁcation and diagnostic
matol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.012
questionnaires.
Patients were included since 2011 according to the1990
American College of Rheumatology Classiﬁcation Criteria for
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Table 1 – Fulﬁllment of the 1990 Classiﬁcation Criteria
for Fibromyalgia (ACR1990) and the 2010 Preliminary
Diagnostic Criteria for Fibromyalgia (ACR2010).
ACR2010
Yes No Total
ACR1990
Yes 347 39 386
No 182 44 226
Total 529 83 612
Table 2 – Clinical parameters of the EpiFibro database
patients.
Parameter Values
PNS 8.4 ± 1.4
FNS 7.9 ± 2.3
PSD 22.19 ± 5.8
FIQ 68.0 ± 17.1
PNS, Pain Numerical Scale (0–10); FNS, Fatigue Numerical Scale
(0–10); PSD, Polisymptomatic Distress Scale; FIQ, Fibromyalgia
Impact Questionnaire.
r-.576
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Fig. 1 – Correlation between the FIQ and PDS.r  e v b r a s r e u m a t o l
ibromyalgia (ACR1990).2 The clinical and epidemiological
ata was already published in 2013.3
In 2010, an ACR committee presented the Preliminary Diag-
ostic Criteria for Fibromyalgia (ACR2010), after two decades of
ritics on the ACR1990. The new criteria abolished the tender
oints counting and emphasized the association of fatigue;
leep disorders, cognitive disorders and somatic symptoms
o chronic widespread pain. It established 2 scores – an
idespread pain index (WPI), composed by 19 potentially
ainful areas to be identiﬁed by the patients, and a symp-
om severity index (SSI) that results from the sum of fatigue,
leep disturbances, cognitive disorders and somatic symp-
oms scores (0–3 each). The total score ranges from 0 to 12.4 In
011 the somatic symptoms item was modiﬁed, which allowed
reating a self-report version in order to be used in epidemio-
ogical studies.5
The sum of these two indices, ranging from 0 to 31,
amed Polysymptomatic Distress Scale (PDS), can be used for
atients’ clinical monitoring.6 The follow-up measures for the
M patients usually are analogical symptoms scales, as for
xample for pain, and by quality of life or impact question-
aires such as the Fibromyalgia Impact Questionnaire (FIQ)
nd its revised form, whose versions have been translated and
alidated to Brazilian Portuguese.7,8
bjectives
he main objectives of the present study are to determine how
any patients still fulﬁll the ACR1990 and the ACR2010 criteria
n 2014, to determine the correlation between the impact of FM
easured by the FIQ and by the PDS and to describe data on the
ollow-up evaluation of the patients enrolled in the registry.
atients  and  methods
his is a cross sectional study in a multicenter cohort of
atients with FM.  The data was collected between 2013
nd 2015, including demographic, clinical information and
ollow-up parameters. Analogical symptom scales of pain and
atigue, FIQ and the PDS were considered clinical parameters.
Patients were included in EpiFibro by their physician,
ccording to a tutorial by the Brazilian Rheumatology Soci-
ty. It included patients that fulﬁlled the ACR1990 criteria
n the date of the patient’s entry in the registry. Patients
ith incomplete forms were excluded as that prevented the
ata analysis for the proposed objectives. The follow-up data
ere considered only for patients with at least two evalua-
ion forms separated by three months interval as a minimum.
 minimally signiﬁcant clinical change was considered to
e a 30% up or down variation of the follow-up parameters
cores.
Descriptive statistics and the Pearson correlation coefﬁ-
ient were used.Please cite this article in press as: Martinez JE, et al. EpiFibro (Brazilian F
preliminary criteria fulﬁllment and the follow-up evaluation. Rev Bras Reu
esults
 total of 810 patients’ data were analyzed. Patients pre-
ented a mean age of 51.8 ± 11.5 years-old. There were786 female patients (97.0%) and only 24 men  (3%). Most
patients were attended in public health care (648 patients
– 80%) and 162 patients (20%) were treated in private
services.
Most patients met  both ACR criteria as shown in Table 1.
There was a greater fulﬁlling of the ACR2010 compared to the
ACR1990, suggesting that the new criteria are more sensitive
and maybe less speciﬁc than the older one.
Table 2 shows clinical data in patients’ self-scored reports.
There was high intensity of pain and fatigue and a severe
disease impact measured by PDS and FIQ.
There was a moderate correlation between PDS and FIQ
(r = 0.576), as shown in Fig. 1.
Three hundred fourteen patient’s registries with more  than
one assessment were found, but 88 patients were excludedibromyalgia Registry): data on the ACR classiﬁcation and diagnostic
matol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.012
because an interval between evaluations under 3 months.
Thus, 226 patients with one follow-up monitoring param-
eter registered were considered (FIQ: 222; PDS: 199; both:
195).
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Table 3 – Evolution parameters of the EpiFibro database ﬁbromyalgia patients.
Parameter First evaluation Last evaluation Improved Worsened Unchanged
FIQ 66.10 ± 19.59 67.06 ± 19.13 37 (16.61%) 21 (9.45%) 164 (73.87%)
PDS 22.53 ± 5.57 19.67 ± 6.67 39 (19.59%) 9 (4.52%) 151 (74.87%)
FIQ, Fibromyalgia Impact Questionnaire; PDS, Polysymptomatic Distress Scale.
rThe mean follow-up time was 9.1 ± 7.5 months (1–44). FIQ
and PDS measures are shown in Table 3.
Discussion
In this study, it was observed a female predominance, which
is compatible with the literature.9 Although there is a large
majority of patients seen in the Brazilian Public Health
System, the private network is also represented in this
study.
The intensity of pain and fatigue and the impact clin-
ical parameters shows that the reported cases are severe.
Higher severity can be justiﬁed by the main data collec-
tion centers involved in this study are universities that
composes the tertiary care health assistance level. So, this
is a limitation of this research that prevents the data to
be generalized to all Brazilian ﬁbromyalgia patients. Any-
way, it suggests a need for epidemiological studies involving
community patients. The same argument may be used for
the high male predominance. It is important to empha-
size that this is not a prevalence study, but a registry
data.
The moderate correlation between the two follow-up
parameters (FIQ and PDS) suggests that both can be used in
monitoring. The choice of the parameter should be based
on the ease of use and the familiarity of the doctors or
services. The FIQ has been used in clinical trials and in
daily practice since 1993 with reliable results in our pop-
ulation even before being validated formally. In 2006, it
was published its formal translation and validation for Por-
tuguese in Brazil. The PDS was recently created and we  still
have not published data to assess its potential for clinical
monitoring.7
The observed clinical stability is compatible with evolu-
tion studies present in the literature. Kennedy et al. studied 35
patients and showed that 100% continued to have symptoms
after 10 years.10 Other studies have reported improvements in
pain over time, but the total resolution of symptoms seems
rare.11,12 In 2011, Walitt et al. published a 5 year follow-up
study with 1555 ﬁbromyalgia patients and found a clinically
signiﬁcant improvement in the overall severity of symptoms,
despite the pain improvement be only moderate in 25% of
patients.13Please cite this article in press as: Martinez JE, et al. EpiFibro (Brazilian F
preliminary criteria fulﬁllment and the follow-up evaluation. Rev Bras Reu
Conclusion
In the EpiFibro Cohort, most patients fulﬁll simultaneously
the ACR1990 and ACR2010 criteria for FM.  A larger number of
1patients fulﬁll the ACR2010 compared to ACR1990 at the time
of the evaluation. There was a moderate correlation between
the FIQ and the PDS monitoring and most patients remained
stable over time.
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